Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Gijon – page 4

57 clinical trials in Gijon, Spain. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Gijon at a glance
57
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

57 trials in Gijon

Open in trial search

Plasma cell myeloma

Not recruiting

Study of belantamab mafodotin with bortezomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma patients eligible for transplant

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Belantamab Mafodotin
  • Sponsor:Fundacion PETHEMA

B-cell lymphoma+2

Not recruiting

Study Comparing Polatuzumab Vedotin with Rituximab, Ifosfamide, Carboplatin, and Etoposide for Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:GWT-Tud GmbH

Plasma cell myeloma

Not recruiting

Study Comparing Talquetamab, Pomalidomide, and Teclistamab for Patients with Relapsed or Refractory Myeloma After 1 to 4 Prior Treatments

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Follicular lymphoma

Not recruiting

Study of Ibrutinib and Rituximab for Patients with Follicular Lymphoma

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Plasma cell myeloma

Not recruiting

Study of Daratumumab with Drug Combination for Patients with Newly Diagnosed Multiple Myeloma Eligible for High-Dose Therapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Cardiac amyloidosis+1

Not recruiting

Study on the Effectiveness and Safety of CAEL-101 with Drug Combination for Patients with Advanced AL Amyloidosis

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Anselamimab
  • Sponsor:Alexion Pharmaceuticals Inc.

Diffuse large B-cell lymphoma

Not recruiting

Study on Acalabrutinib with Drug Combination for Patients 75 and Older with Untreated Diffuse Large B-Cell Lymphoma

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Acerta Pharma B.V.

Cardiac amyloidosis+1

Not recruiting

Study on the Effectiveness and Safety of CAEL-101 with Plasma Cell Dyscrasia Treatment in Patients with Stage IIIa AL Amyloidosis

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Anselamimab
  • Sponsor:Alexion Pharmaceuticals Inc.

Colitis ulcerative

Not recruiting

Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Relapsing multiple sclerosis

Not recruiting

Study on the Effectiveness and Safety of Remibrutinib Compared to Teriflunomide for Patients with Relapsing Multiple Sclerosis

Registered drug
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Charcoal, Activated
  • Sponsor:Novartis Pharma AG

Plasma cell myeloma

Not recruiting

Study Comparing Belantamab Mafodotin with Pomalidomide and Dexamethasone to Bortezomib with Pomalidomide and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Belantamab Mafodotin
  • Sponsor:Glaxosmithkline Research & Development Limited

Plasma cell myeloma refractory

Not recruiting

Study Comparing Teclistamab with Daratumumab, Pomalidomide, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Gijon

What the registry says about research in the country

01 Hematologic Malignancies

Extensive research focusing on multiple myeloma and various lymphomas, including innovative combination therapies and novel treatment approaches for previously untreated and relapsed/refractory cases.

  • Mantle Cell Lymphoma
  • Multiple Myeloma
  • Chronic Lymphocytic Leukemia

Studies evaluating breakthrough treatments like acalabrutinib, belantamab mafodotin, and linvoseltamab.

02 Gastrointestinal Disorders

Clinical investigations targeting various digestive system conditions, with particular emphasis on pancreatic diseases and inflammatory bowel conditions.

  • Ulcerative Colitis
  • Pancreatic Adenocarcinoma
  • Biliary Pancreatitis

Research includes both therapeutic interventions and surgical approaches for optimal patient outcomes.

03 Cardiovascular Research

Innovative studies examining treatments for coronary artery conditions and vascular events, with focus on both preventive measures and therapeutic interventions.

  • Spontaneous Coronary Artery Dissection
  • Antiplatelet Therapy
  • Chronic Renal Disease

Investigations into beta-blockers, antiplatelet agents, and colchicine for various cardiovascular conditions.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.